Why this trial matters : First ADC to move into the 1L HER2+ metastatic setting Breaks a decade-long treatment paradigm in first-line breast cancer care Confirms ADCs as frontline platforms, not just late-line salvage therapies Roche Giredestrant Delivers the First Phase III Win for an Oral SERD in Early Breast Cancer Roches oral SERD giredestrant reduced the risk of invasive disease recurrence versus standard endocrine therapy in the Phase III lidERA trial in ER-positive, HER2-negative early breast cancer, marking the first major advance in adjuvant endocrine therapy in decades
This function boosts the production of repair enzymes, leading to faster healing
Research Applications (In Vitro / Laboratory Only) Tissue Repair Models: First, researchers study how BPC-157 affects wound and repair cell models
Curr Cardiol Rep
Chao cautions that Semaglutide is such a potent appetite suppressor that many people have a difficult time getting in enough protein to build muscle. He continues, Most people on Ozempic struggle to eat 800 to 1200 calories a day, which is nowhere near enough volume of food to support muscle hypertrophy. To correct this problem, people are encouraged to focus on strength-training exercises such as squats, lunges, hip thrusts and deadlifts
Amen SL, Piacentine LB, Ahmad ME, Li SJ, Mantsch JR, Risinger RC, et al
